Castle Biosciences is a leading diagnostics company that provides personalized, clinically actionable information to clinicians and patients to inform treatment decisions and improve health outcomes. The company is focused on transforming the disease management paradigm leveraging advanced technologies for its portfolio of innovative tests for skin cancers, uveal melanoma and Barrett’s esophagus. (www.CastleTestInfo.com)
Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions.
DecisionDx®-Melanoma predicts risk of recurrence or metastasis that can inform decisions regarding sentinel lymph node biopsy and the intensity of follow-up, surveillance imaging, referral, and adjuvant therapy for patients with invasive cutaneous melanoma. The test uses tumor biology to provide an individual risk of melanoma recurrence beyond traditional factors such as AJCC staging criteria and integrates the 31-GEP score with clinicopathologic factors to provide a more precise and personalized risk of recurrence (i31-ROR) and sentinel lymph node positivity (i31-SLNB) prediction. DecisionDx-Melanoma is supported by consistent evidence in over 30 publications including two meta-analyses showing Level 1 evidence classification.
We provide the most comprehensive gene expression profile (GEP) diagnostic workflow designed to aid in characterizing difficult-to-diagnose melanocytic lesions. Our diagnostic offering includes two tests, myPath® Melanoma and DecisionDx® DiffDx®-Melanoma, leveraging the strengths of both to provide a highly accurate, objective evaluation for a more confident and actionable patient management plan.
DecisionDx®-SCC accurately identifies risk of metastasis in high-risk squamous cell carcinoma (SCC) patients with one or more risk factors. The incorporation of DecisionDx-SCC results with traditional risk factors provides additional risk prediction to better inform choices about treatment and follow-up care.
DecisionDx®-UM predicts risk of metastasis for patients with uveal melanoma, a rare eye cancer. The test is standard of care in a majority of ocular oncology practices.
TissueCypher® Barrett’s Esophagus Assay is the first and only precision medicine test that can predict the future development of esophageal cancer in patients with Barrett’s esophagus and is an independent risk predictor from tissue histology and other clinical risk factors. The test is intended for patients with a confirmed diagnosis of Barrett’s esophagus graded non-dysplastic, indefinite for dysplasia or low-grade dysplasia, and provides a five-year risk of progression to high-grade dysplasia or esophageal adenocarcinoma.
To learn more, visit www.CastleTestInfo.com or www.CastleBiosciences.com .